Summary
Thermo Fisher Scientific Inc. (TMO) announced a significant executive appointment and a departure via an 8-K filing on July 17, 2017, related to events on July 11, 2017. Mark P. Stevenson has been appointed Executive Vice President and Chief Operating Officer, effective August 1, 2017. This new role expands his operational oversight to include the Laboratory Products and Analytical Instruments businesses, in addition to his existing responsibilities for the Life Sciences Solutions business. Mr. Stevenson's extensive experience, including his leadership at Life Technologies and Applied Biosystems, positions him to drive further operational integration and growth across key segments of the company.
Key Highlights
- 1Mark P. Stevenson appointed Executive Vice President and Chief Operating Officer, effective August 1, 2017.
- 2Stevenson's role expands to encompass operational oversight of Laboratory Products and Analytical Instruments, in addition to Life Sciences Solutions.
- 3This appointment signifies a consolidation of operational leadership under a key executive with prior experience in acquired entities (Life Technologies).
- 4Thomas W. Loewald, a named executive officer, has notified the Company of his resignation, effective September 1, 2017.
- 5The filing incorporates by reference disclosures regarding legacy Life Technologies equity awards for Mr. Stevenson from a prior proxy statement.
- 6The effective date of the executive changes is August 1, 2017, with the resignation effective September 1, 2017.
Frequently Asked Questions
This 8-K filing announces a key executive appointment and an executive resignation. Mark P. Stevenson has been promoted to Executive Vice President and Chief Operating Officer, and Thomas W. Loewald is resigning from his position.
As Executive Vice President and Chief Operating Officer, Mr. Stevenson will have operational oversight of the Company’s Laboratory Products and Analytical Instruments businesses, in addition to his existing responsibility for the Life Sciences Solutions business.
Mark P. Stevenson's appointment is effective August 1, 2017. Thomas W. Loewald's resignation is effective September 1, 2017.
The filing notes that required disclosures regarding the vesting of certain legacy Life Technologies equity held by Mr. Stevenson were previously included in the Company’s definitive proxy statement on Form 14A filed on April 4, 2017. This 8-K does not introduce new compensation details but refers to prior disclosures.